Items where authors include "Fox, C.P."

Article

Abhishek, A. orcid.org/0000-0003-0121-4919, Grainge, M., Card, T. orcid.org/0000-0003-2555-2250 et al. (8 more authors) (2024) Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10 (1). e003980. ISSN 2056-5933

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Abhishek, A. orcid.org/0000-0003-0121-4919, Stevenson, M.D. orcid.org/0000-0002-3099-9877, Nakafero, G. orcid.org/0000-0002-3859-7354 et al. (12 more authors) (2023) Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology. ljad430. ISSN 0007-0963

Hesselbo, S.P. orcid.org/0000-0001-6178-5401, Al-Suwaidi, A. orcid.org/0000-0002-4677-6651, Baker, S.J. et al. (70 more authors) (2023) Initial results of coring at Prees, Cheshire Basin, UK (ICDP JET project): towards an integrated stratigraphy, timescale, and Earth system understanding for the Early Jurassic. Scientific Drilling, 32. pp. 1-25. ISSN 1816-8957

Nakafero, G. orcid.org/0000-0002-3859-7354, Card, T., Grainge, M.J. et al. (9 more authors) (2023) Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64. 102213. ISSN 2589-5370

Nakafero, G. orcid.org/0000-0002-3859-7354, Grainge, M.J., Williams, H.C. et al. (9 more authors) (2023) Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381. e074678. ISSN 0959-8138

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045